Wegovy injection benefits: what clinical trials and UK guidance show

What the STEP 1 trial actually measured — and why it matters

Clinical trials are easy to cite and hard to contextualise. The STEP 1 results (around 15% average body-weight reduction over 68 weeks at semaglutide 2.4mg) were recorded in adults who had obesity or overweight with at least one weight-related condition, most of whom had tried and struggled with other approaches before. The trial wasn't small: 1,961 participants across multiple countries, with consistent results across subgroups. NHS guidance on semaglutide summarises the licensed uses and what those results mean for people considering treatment.

That 15% average matters because it sits well above what most people achieve with diet and activity alone, and because it is an average. Some participants lost considerably more; others less. Weight loss with any GLP-1 medicine is shaped by individual biology, how consistently the medicine is taken, and the lifestyle changes made alongside it. The trial protocol included regular dietary counselling, a detail worth holding onto when you read headline numbers.

NICE reviewed this evidence in detail before recommending semaglutide (Wegovy) for use within specialist weight-management services, subject to specific BMI and comorbidity criteria. You can read NICE's full reasoning in Technology Appraisal 875.

Beyond the number on the scales: documented secondary benefits of semaglutide injections

Weight reduction at this scale rarely happens in isolation. Trials in the STEP programme tracked a range of health markers alongside body weight, and the findings extended into cardiovascular risk, blood pressure, waist circumference, and blood-sugar regulation. For people who carry weight-related conditions (hypertension, dyslipidaemia, pre-diabetes) those secondary shifts can matter as much as the weight figure itself.

Semaglutide's cardiovascular benefit has since been formally recognised in the UK: Wegovy holds a separate MHRA licence for reducing the risk of major cardiovascular events in eligible adults, independent of its weight-management indication. That isn't a marketing claim; it reflects a distinct regulatory decision based on its own trial evidence.

The once-weekly injection schedule is itself a practical benefit for many people. A single pen covers four weeks of doses, which means treatment fits quietly into most routines rather than demanding daily attention. Our guide to using the Wegovy injection covers technique, rotation sites, and how to handle the pen correctly from the first dose.

If you're currently exploring whether weekly injections are the right format for you, our overview of weight-loss injection options sets out how the available treatments differ.

Who tends to benefit most, and what the licence says about eligibility

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or for those with a BMI between 27 and 29.9 who have at least one weight-related condition. Lower thresholds apply for some ethnic backgrounds under UK guidance, 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. BMI, though, is only one part of the picture a prescriber looks at.

The people who tend to see the most sustained benefit are those who use the injection consistently, titrate slowly enough for their system to adjust, and pair treatment with genuine changes to diet and activity. That's not a caveat designed to lower expectations, it's what the trial data consistently shows. The semaglutide injection benefits described in published research were achieved by participants who were actively supported throughout.

Practical things matter too. One question our prescribers hear regularly is about timing orders around holidays or busy weeks. The process for getting Wegovy through a regulated UK pharmacy takes that into account, orders placed by 12pm Monday to Friday are dispatched the same day once approved, which makes it straightforward to plan around a payday, a bank holiday, or a week away.

If you want to read about the arm as a specific injection site, this page covers technique and what to expect.

The 7.2mg dose: a newer option and what its evidence adds

In January 2026 the MHRA approved semaglutide 7.2mg as an extended maintenance dose, initially delivered as three 2.4mg pens weekly. A dedicated single-dose 7.2mg pen followed in April 2026, the first of its kind, with an auto-dosing mechanism and a built-in covered needle that locks after use. The pen is approved for adults with a BMI of 30 or above only, and the titration pathway still starts at 0.25mg, rising through the established schedule before reaching 7.2mg as the maximum.

Trial data at this higher dose showed around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide 15mg considerably compared to the 2.4mg results. Whether 7.2mg is appropriate for a given patient depends on tolerability at lower doses and a prescriber's clinical judgement; it isn't a starting point. If you want to understand how the individual Wegovy injection s within the titration sequence work and what each step involves, that can help clarify what to expect before committing to treatment. Specific dose availability is confirmed during consultation rather than assumed upfront.

For a fuller picture of the semaglutide injection and the titration pathway from the first pen onwards, the Wegovy injection overview covers the licensed schedule, storage, and what to expect across the early weeks. If you're thinking about whether treatment might suit your situation, checking your eligibility is a straightforward first step.